Kristin Burns-Huang, Ph.D., is an Associate Director, Project Management, Deerfield Discovery and Development and joined the Firm in 2022. Prior to Deerfield, Dr. Burns-Huang spent 10 years at Weill Cornell Medicine as a Research Assistant Professor, Research Coordinator, and Lab Manager in the lab of Dr. Carl Nathan. Dr. Burns-Huang holds a B.A. in Chemistry from Franklin and Marshall College, and a Ph.D. in Biochemistry from Cornell University.

Marc Feiglin is Head of Innovative Technologies, Deerfield Discovery and Development, and joined the Firm in 2022 to work on the “Lab of the Future” project. Prior to joining Deerfield, Mr. Feiglin was a Senior Director, External Innovation, Corporate Development & Strategy at Thermo Fisher Scientific. Before that, Mr. Feiglin spent five years at Merck KGaA in various roles, most recently as Senior Director Alliance Management & Partnerships, Electronic Materials. Mr. Feiglin holds a B.S. in Biology from University of Michigan, and an M.B.A. jointly awarded by New York University, London School of Economics and HEC Paris.

Huijun Wang, Ph.D., is the Head of Computational Drug Design, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Wang was most recently Director, Computational Drug Design at Agios Pharmaceuticals, where she worked for three years. Before Agios, she was an Associate Principal Scientist, Modeling and Informatics at Merck for more than five years and a Senior Scientist at Pfizer for more than three years. Dr. Wang holds a B.Sc. in Chemistry and a B.A. in Economics from Peking University in China, and an M.Sc. in Chemical Informatics, an M.Sc. in Computer Science, and a Ph.D. in Informatics from Indiana University Bloomington.

Abdul Khan, Ph.D., is a Director, Biologics, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Khan was a Director, Protein Engineering at Molecular Templates for a year. Before this, he was most recently Senior Associate Director, Protein and Cell Line Engineering for Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), where he worked for more than five years. Dr. Khan holds a B.S. in Chemistry, Zoology, and Botany, an M.S. in Zoology, a Master of Philosophy in Molecular Biology from Punjab University, Pakistan, and a Ph.D. in Natural Sciences from University of Vienna, Austria.

Ankita Shah, Ph.D.,is a Principal Scientist, Drug Product Development, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Shah spent four years at Freund-Vector Corporation, most recently as Senior Process Development Scientist. Dr. Shah holds a Bachelor of Pharmacy from L.M. College of Pharmacy in India, and an M.S. and a Ph.D. in Pharmaceutical Sciences from St. John’s University.

Carla Gauss, Ph.D., is a Senior Director, Medicinal Chemistry, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Gauss was a Senior Application Scientist, Medicinal Chemistry at Nanome. Before Nanome, she served as a Research Investigator at Cold Spring Harbor Laboratory, where she worked for 11 years. Before this, Dr. Gauss held various positions as a scientist at Progenics Pharmaceuticals, Cara Therapeutics, Memory Pharmaceuticals and Exelixis. Dr. Gauss holds a B.S. in Chemistry and a B.A. in Biology from University of Virginia and a Ph.D. in Organic Chemistry from University of California at Irvine.

Eric Schiffhauer, Ph.D., is a Director, Academic Outreach, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Schiffhauer spent three years at Northwestern University, most recently as a Scientific Collaboration Director. Before Northwestern, he held positions at Adi Family Office and Johns Hopkins Technology Ventures. Dr. Schiffhauer holds a B.S. in Biology from George Mason University and a Ph.D. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.

Carrie Wei, Ph.D., is a Director, Drug Metabolism and Pharmacokinetics, Deerfield Discovery and Development, and joined the Firm in 2022.  Prior to Deerfield, Dr. Wei spent three years at Biogen as an Associate Director and Team Leader, Drug Metabolism and Pharmacokinetics.  Before Biogen, Dr. Wei was a Group Leader and Principal Scientist, Drug Metabolism and Pharmacokinetics at Vertex Pharmaceuticals for three years and held various other roles of increasing responsibilities at Bristol Myers Squibb and Pfizer.  Dr. Wei holds a B.S. in Biological Sciences from Wuhan University, an M.S. in Biological Sciences and Neuroscience from Purdue University, and a Ph.D. in Pharmacology from University of Pennsylvania.